Here are nine takeaways:
1. SeaSpine’s revenue totaled $31.4 million in the first quarter 2016, a 2.8 percent decline compared to the first quarter of 2015.
2. The company’s net loss for the first quarter of 2016 was $12 million, up from a net loss of $9.9 million in the first quarter of 2015.
3. Revenue from orthobiologics products totaled $16.7 million, a 3.9 percent increase from the first quarter of 2015. U.S. orthobiologics product revenue was $14.9 million in this quarter.
4. Revenue from spinal hardware totaled $14.7 million, down 9.5 percent from the same period last year.
5. U.S. spinal hardware product revenue reached $13.6 million, a 9.7 percent decrease compared to the first quarter of 2015.
6. The company attributed the decline in spinal hardware sales to “continued mid-single digit pricing pressure in the U.S. and lower case volume on legacy products.”
7. Operating expenses for the first quarter of 2016 totaled $29.4 million, a $1.4 million increase compared to the same period.
8. Additionally, research and development expenses totaled $2.8 million, 8.8 percent of revenue.
9. SeaSpine continues to expect full-year 2016 revenue to be in a range of $136 million to $140 million, reflecting 2 percent to 5 percent growth over full-year 2015 revenue.
More articles on devices:
Vertebral Technologies launches pedicle screw system: 5 key notes
MiMedx to attend Craig-Hallum Institutional Investor Conference — 3 quick notes
Congress of the Chinese Association of Orthopedic Surgeons Meeting features Misonix’s BoneScalpel — 4 takeaways
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
